Adult Chronic Immune Thrombocytopenia (ITP)
Target: Spleen tyrosine kinase (SYK)
| Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
|
Pre-Clinical
Complete
|
Phase 1
Complete
|
Phase 2
Complete
|
Phase 3
Complete
|
Approved
Complete
|
R/R Acute Myeloid Leukemia
Target: Mutant isocitrate dehydrogenase–1 (mIDH1)
| Pre-clinical | Phase 1 | Phase 2 | NDA FILED | Approved |
|---|---|---|---|---|
|
Pre-clinical
Complete
|
Phase 1
Complete
|
Phase 2
Complete
|
NDA FILED
Complete
|
Approved
Complete
|
COVID-19
Target: Spleen tyrosine kinase (SYK)
| Pre-clinical | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
|
Pre-clinical
Complete
|
Phase 1
Complete
|
Phase 2
Complete
|
Phase 3
Complete
|
Approved
Not Started
|
COVID-19
Target: Spleen tyrosine kinase (SYK)
| Pre-clinical | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
|
Pre-clinical
Complete
|
Phase 1
Complete
|
Phase 2
Complete
|
Phase 3
In Progress
|
Approved
Not Started
|
LR-MDS & Immune Diseases
Target: Interleukin receptor-associated kinases 1 and 4 (IRAK1/4)
| Pre-clinical | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
|
Pre-clinical
Complete
|
Phase 1
Complete
|
Phase 2
Not Started
|
Phase 3
Not Started
|
Approved
Not Started
|
Adult Chronic ITP
Target: Spleen tyrosine kinase (SYK)
| Pre-clinical | Phase 1 | Phase 2 | Japan Phase 3 | Approved |
|---|---|---|---|---|
|
Pre-clinical
Complete
|
Phase 1
Complete
|
Phase 2
Complete
|
Japan Phase 3
Complete
|
Approved
Complete
|
Liposarcoma
Target: Murine double minute 2 (MDM2)
| Pre-clinical | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
|
Pre-clinical
Complete
|
Phase 1
Complete
|
Phase 2
Complete
|
Phase 3
In Progress
|
Approved
Not Started
|
NSCLC & COVID-19
Target: AXL receptor tyrosine kinase (AXL)
| Pre-clinical | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
|
Pre-clinical
Complete
|
Phase 1
Complete
|
Phase 2
In Progress
|
Phase 3
Not Started
|
Approved
Not Started
|
Immune Diseases
Target: Receptor-interacting serine/threonine-protein kinase 1 (RIPK1)
| Pre-clinical | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
|
Pre-clinical
Complete
|
Phase 1
Complete
|
Phase 2
Not Started
|
Phase 3
Not Started
|
Approved
Not Started
|
CNS Diseases
Target: Receptor-interacting serine/threonine-protein kinase 1 (RIPK1)
| Pre-clinical | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
|
Pre-clinical
In Progress
|
Phase 1
Not Started
|
Phase 2
Not Started
|
Phase 3
Not Started
|
Approved
Not Started
|
1 Please see the TAVALISSE Full Prescribing Information
2 Please see the REZLIDHIA Full Prescribing Information, including Boxed WARNING
3 This project has been funded in part by the U.S. Government under Agreement W911QY-21-9-0018
4 Coordinated by Vanderbilt University Medical Center and funded by National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH)
* Investigational compounds in these indications have not been submitted for FDA review